Advertisement

Topics

Latest "Achillion Reports Preliminary Proof Concept With 4471 Treatment" News Stories - Page: 2

11:46 EDT 24th March 2019 | BioPortfolio

Here are the most relevant search results for "Achillion Reports Preliminary Proof Concept With 4471 Treatment" found in our extensive news archives from over 250 global news sources.

More Information about Achillion Reports Preliminary Proof Concept With 4471 Treatment on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Achillion Reports Preliminary Proof Concept With 4471 Treatment for you to read. Along with our medical data and news we also list Achillion Reports Preliminary Proof Concept With 4471 Treatment Clinical Trials, which are updated daily. BioPortfolio also has a large database of Achillion Reports Preliminary Proof Concept With 4471 Treatment Companies for you to search.

Showing "Achillion Reports Preliminary Proof Concept With 4471 Treatment" News Articles 26–50 of 22,000+

Friday 22nd March 2019

FDA Approves Ketamine Derivative as Depression Treatment for First Time

Treatment-resistant depression affects 1 in 3 of the estimated 16.2 million adults in the U.S. who have suffered at least one major depressive episode. For them, two or more therapies have failed and the risk of suicide is much greater. It’s a grim prognosis. There are few therapies for depression that resists treatment, which is why the FDA granted this new drug application Fast Track and Brea...


EU Approval Sought for Frontline Daratumumab/Rd in Transplant-Ineligible Myeloma

A Type II variation application has been submitted to the European Medicines Agency for the combination of daratumumab with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation.

Physicians Realty Trust Declares Quarterly Cash Dividend and Announces Date for First Quarter 2019 Earnings Release and Conference Call

Physicians Realty Trust (NYSE:DOC) (the “Company”) announced today that the Company’s Board of Trustees has authorized and the Company has declared a quarterly cash dividend of $0.23 per common share and unit for the quarter ending March 31, 2019. “We are proud to declare and pay our 23rd consecutive quarterly dividend. Medical office cont...


Teva Announces Launch of a Generic Version of EXJADE® (deferasirox) Tablets For Oral Suspension in the United States

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of a generic version of EXJADE®1 (deferasirox) Tablets for Oral Suspension, 125 mg, 250 mg and 500 mg, in the U.S. Deferasirox Tablets for Oral Suspension are an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in ...

FDA: Higher Risk for Death Found With Venclexta in Multiple Myeloma

FRIDAY, March 22, 2019 -- A safety statement was issued yesterday by the U.S. Food and Drug Administration regarding risks found to be associated with the investigational use of Venclexta (venetoclax) for treatment of patients with multiple...

STAT Plus: With a potential annual tab running from $33,000 to $49,200, a preliminary analysis says J&J's esketamine fails to provide sufficient value. https://buff.ly/2CzPh9w 

STAT Plus: With a potential annual tab running from $33,000 to $49,200, a preliminary analysis says J&J's esketamine fails to provide sufficient value. https://buff.ly/2CzPh9w 

Medicrea Reports 2018 Annual Results

2018 Annual Sales: € 32.3M, +22% at Constant Exchange RateStrong Growth of UNiD® Surgeries in the USA: +67%Gross Margin Jumping to 77% in the 4th QuarterEBITDA at Break-Even in H2 2018Positive EBITDA Expected for 2019 A Unique Model in Patient-Specific Spine Surgery Based on Artificial Intelligence and Large Industrial Capacity The M...

AUDIO: Podcast: Gottlieb Addresses LDT Legislation At Brookings

US FDA Commissioner Scott Gottlieb spoke with Medtech Insight about the agency’s decision to put the LDT issue to Congress...   

STAT Plus: J&J’s new esketamine drug for depression may solve an unmet need, but may not be cost-effective

With a potential annual tab running from $33,000 to $49,200, a preliminary analysis says J&J's esketamine fails to provide sufficient value.

Life Science Big News Roundup: RISE Announces Hemp-based CBD Products for Sports Recovery and PMS; Kalytera Reports Data for First Cohort in Phase 2 Clinical Study

In case you missed it, here is this week’s life science big news roundup. The post Life Science Big News Roundup: RISE Announces Hemp-based CBD Products for Sports Recovery and PMS; Kalytera Reports Data for First Cohort in Phase 2 Clinical Study appeared first on Investing News Network.

Biogen Halts Studies of Closely Watched Alzheimer's Drug, a Blow to Hopes for New Treatment http://dlvr.it/R1M0tF pic.twitter.com/DTMDpQb679

Biogen Halts Studies of Closely Watched Alzheimer's Drug, a Blow to Hopes for New Treatment http://dlvr.it/R1M0tF  pic.twitter.com/DTMDpQb679

Biogen and Eisai remain committed after discontinuation of ENGAGE and EMERGE programmes

22 March 2019 – Pharmaceutical companies Biogen and Eisai have announced the discontinuation of two Phase 3 trials of aducanumab. The decision came after analysis by an independent monitoring committee indicated the trials were unlikely to succeed. Biogen and Eisai will continue to investigate other treatments for Alzheimer’s disease, including anti-amyloid treatment BAN2401....

Research identifies guidelines for prioritizing hepatitis C treatment in U.S. prisons

New research identifies guidelines for prioritizing the treatment of hepatitis C infections in the U.S. prison system, resulting in a significant improvement in health outcomes of incarcerated persons while simultaneously reducing new infections in the society.

Bipartisan lawmakers urge Administration to rethink proposed changes to six protected classes policy

At the end of 2018, the Centers of Medicare & Medicaid Services (CMS) introduced a dangerous proposed rule that would weaken the Medicare Part D six protected classes policy. The six protected classes policy covers patients whose conditions – like HIV, cancer, and epilepsy among others - are treated with medicines covered under six specific drug classes. T

Antidepressant drugs may not work when neurons are out of shape

elective serotonin reuptake inhibitors are the most commonly prescribed medication for major depressive disorder, yet scientists still do not understand why the treatment does not work in nearly thirty percent of patients with MDD.

ER Doc Survives Cancer, Now Must Survive ER

A Florida-based ER physician with an aggressive lymphoma underwent a 'miracle' treatment but now has a weakened immune system. Back at work, now he has to survive the ER and its germs. Medscape Medical News

Cerveau Technologies Inc. Signs Research Agreement with Eisai Inc., for Novel Tau Imaging Agent

Cerveau Technologies, Inc. today announced a research collaboration agreement with Eisai Inc., which will enable Eisai to use Cerveau’s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography (PET) scans to assess the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are...

Assisted Dying: Doctors’ Group Adopts Neutral Position

(BBC) – Hospital doctors have dropped their 13-year opposition to the concept of helping terminally ill patients die. Following a poll of its members, the Royal College of Physicians has now adopted a neutral stance on the issue of assisted … Read More

'Cancer' Label for Low-Risk Lesions Could Lead to Overtreatment

Using the term 'cancer' to describe low-risk lesions rather than a more benign word could tip patients into paradoxical treatment choices that worsen their prognosis because of fear, say US researchers. Medscape Medical News

Human Genomics Research Has a Diversity Problem

(NPR) – Precision medicine promises to tailor the diagnosis and treatment of disease to your unique genetic makeup. A doctor may use the presence of certain genetic markers to diagnose a disease, or choose one drug for treatment over another. … Read More

Eli Lilly and Company: Eli Lilly and Company calls company stockholders meeting

Eli Lilly and Company Eli Lilly and Company: Eli Lilly and Company calls company stockholders meeting 22-March-2019 / 14:50 CET/CEST Dissemination of a French Regulatory News, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. ELI LILLY AND COMPANY CALLS STOCKH

FDA Warns About the Risks Associated with the Investigational Use of Venclexta in Multiple Myeloma

[3/21/2019] The U.S. Food and Drug Administration is alerting health care professionals, oncology clinical investigators and patients about the risks associated with the investigational use of Venclexta (venetoclax) for the treatment of patients with multiple myeloma based on data from a clinical trial. Venclexta is not approved for the treatment of multiple myeloma. FDA reviewed data …

OncLive® Presents State of the Science Summit™ on Ovarian Cancer and Soft Tissue Sarcoma

The summit will feature expert faculty from Memorial Sloan Kettering Cancer Center OncLive®, the nation’s leading digital resource focused on providing oncology professionals with the most current and insightful information they need to provide the best patient care, will host its latest State of the Science Summit™ on ovarian cancer and soft tiss...

Impulse Dynamics Receives FDA Approval for Breakthrough Optimizer Smart System Delivering CCM Therapy for Treatment of Heart Failure

ORANGEBURG, New York, March 21, 2019 /PRNewswire/ — Impulse Dynamics, developer of the implantable Optimizer® Smart System for delivering CCM™ therapy, announced today that it has received approval from the United States Food and Drug Administration for its first-in-class Optimizer Smart System (link to FDA announcement:  https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm...

Key Trials Seek to Expand on Efficacy, Tolerability of Treatment Regimens in Refractory CRC

Iman Imanirad, MD, discusses these trials in depth and their impact on patients with refractory metastatic colorectal cancer.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks